L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each)
Primary Mediastinal Large B-Cell Lymphoma
Explore 81 assets in Primary Mediastinal Large B-Cell Lymphoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05359211CT.gov NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Mediastinal Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each) (this asset) | Fred Hutchinson Cancer Center | P1 | CC · 43 |
| Isocyclophosphamide | David Bond, MD | P4 | BBB |
| Adriamycin | University of Washington | P4 | BBB |
| Etoposide | University of Washington | P4 | BBB |
| (+)-Vincristine | Sun Yat-sen University | P4 | BBB |
| Axicabtagene Ciloleucel | AIDS Malignancy Consortium | P2 | BB |
| Vincristine Sulfate | National Research Center for Hematology, Russia | P3 | BB |
| Prednisone | University of Washington | P3 | BB |
| Cytarabine | Fred Hutchinson Cancer Center | P4 | BB |
+42 more in the Primary Mediastinal Large B-Cell Lymphoma cohort
Other indications for L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P2/3 | CCC · 53 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P2/3 | CCC · 53 |
| Lung Cancer | — | P2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each) in Primary Mediastinal Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/l-methionyl-interleukin-15-human-non-glycosylated-produced-in-escherichia-coli-substituted-on-an-average-of-one-site-among-n2-of-met1-andor-n6-of-lysyl-residues-with-4-alpha-methylpolyoxyethylene-omega-oxybutanoyl-groups-40-kda-each-primary-mediastinal-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →